Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications
- 1 February 2004
- journal article
- clinical trial
- Published by Elsevier in Schizophrenia Research
- Vol. 66 (2-3) , 163-167
- https://doi.org/10.1016/s0920-9964(03)00153-1
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective DisorderAmerican Journal of Psychiatry, 2001
- Nicotine Transdermal Patch and Atypical Antipsychotic Medications for Smoking Cessation in SchizophreniaAmerican Journal of Psychiatry, 2000
- Elevated Levels of Insulin, Leptin, and Blood Lipids in Olanzapine-Treated Patients With Schizophrenia or Related PsychosesThe Journal of Clinical Psychiatry, 2000
- Body weight gain induced by antipsychotic drugs: mechanisms and managementActa Psychiatrica Scandinavica, 1999
- Smoking and schizophreniaJournal of Psychiatric and Mental Health Nursing, 1997
- Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumptionClinical Pharmacology & Therapeutics, 1994
- Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers.Journal of Clinical Investigation, 1994
- Daily Use of Smokeless Tobacco: Systemic EffectsAnnals of Internal Medicine, 1989
- Pharmacologic Aspects of Cigarette Smoking and Nicotine AddictionNew England Journal of Medicine, 1988
- Prevalence of smoking among psychiatric outpatientsAmerican Journal of Psychiatry, 1986